Gemmer Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Gemmer Asset Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-160	Closed	-$4K	–	1293
2017 Q2	$4K	Hold	160	–	–	﹤0.01%	1039
2017 Q1	$3K	Hold	160	–	–	﹤0.01%	1138
2016 Q4	$2K	Hold	160	–	–	﹤0.01%	1172
2016 Q3	$2K	Hold	160	–	–	﹤0.01%	1181
2016 Q2	$2K	Hold	160	–	–	﹤0.01%	1174
2016 Q1	$2K	Hold	160	–	–	﹤0.01%	1131
2015 Q4	$3K	Hold	160	–	–	﹤0.01%	1036
2015 Q3	$3K	Hold	160	–	–	﹤0.01%	1025
2015 Q2	$4K	Buy	+160	New	+$4.54K	﹤0.01%	952

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

ECP

Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Gemmer Asset Management's PRTK Position: Q3 2017 in Review

Gemmer Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2017, closing a stake of 160 shares — an estimated $4K sold.

Gemmer Asset Management first reported a position in PRTK in Q2 2015 and held it in 9 quarters. The position peaked at $4K in Q2 2017. 133 funds tracked by Wall St. Rank hold PRTK as of Q3 2017.

Gemmer Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Gemmer Asset Management sold 160 Paratek Pharmaceuticals, Inc. shares in Q3 2017, an estimated $4K.
Gemmer Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2015 and held it in 9 quarters.
Gemmer Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $4K in Q2 2017.
133 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2017.

Based on Gemmer Asset Management's 13F filing for Q3 2017, filed 12 Oct 2017.